Business Medical Dialogues
    • facebook
    • twitter
    Login Register
    • facebook
    • twitter
    Login Register
    • Medical Dialogues
    • Speciality Dialogues
    • Education Dialogues
    • Medical Jobs
    • Medical Matrimony
    • MD Brand Connect
    Business Medical Dialogues
    • News
        • Financial Results
        • Hospitals & Diagnostics
        • IT / Health Venture
        • Implants / Devices
        • Insurance
        • Key Movement
        • Pharmaceuticals
        • Policy
        • Technology
        • pharma-news
    • blog
    LoginRegister
    Business Medical Dialogues
    LoginRegister
    • Home
    • News
      • Financial Results
      • Hospitals & Diagnostics
      • IT / Health Venture
      • Implants / Devices
      • Insurance
      • Key Movement
      • Pharmaceuticals
      • Policy
      • Technology
      • pharma-news
    • blog
    • Home
    • Latest News
    • Lupin pushes Nifty...

    Lupin pushes Nifty Pharma index higher by 1 percent

    Written by supriya kashyap kashyap Published On 2017-07-09T09:16:05+05:30  |  Updated On 9 July 2017 9:16 AM IST
    Lupin pushes Nifty Pharma index higher by 1 percent

    Mumbai : Pharma major, Lupin Limited during morning’s trade was rallying on the bourses, helping the Nifty Pharma to gain over 1 percent in the opening trade, making it the top performing index among other sectoral indices.


    The stock was also heavily contributing to the BSE Healthcare index gains by nearly 70%. Followed by Lupin, Dr Reddy’s and Sun Pharma were also pushing the index to higher levels.


    Shares of Lupin were trading up by 3.6%, Dr Reddy’s was up by 1.9% and Sun Pharma was up by 1.25% at around 0944 hours.


    Other stocks in the sectoral index such as Kopran was up by 3.29%, Marksans was up by 3.24%, Ajanta Pharma was up by 2.4%, Divi’s Labs was up by 1.9% and Glenmark was up by 1.5%.


    Meanwhile, IOL Chemical & Pharmaceuticals down by 3.14%, Caplin Point was down by 2.7%, AstaZeneca was down by 1.1%, Hester Biosciences was down by 0.8% and Granules was down by 0.8% at around the time.


    Stock view:


    Lupin Ltd is currently trading at Rs 1121.2, up by Rs 39.95 or 3.69% from its previous closing of Rs 1081.25 on the BSE.


    The scrip opened at Rs 1089.7 and has touched a high and low of Rs 1126 and Rs 1085 respectively. So far 1462349(NSE+BSE) shares were traded on the counter. The current market cap of the company is Rs 48842.65 crore.


    The BSE group 'A' stock of face value Rs 2 has touched a 52 week high of Rs 1750 on 29-Jul-2016 and a 52 week low of Rs 1036.8 on 05-Jul-2017. Last one week high and low of the scrip stood at Rs 1108 and Rs 1036.8 respectively.


    The promoters holding in the company stood at 46.69 % while Institutions and Non-Institutions held 41.24 % and 12.06 % respectively.


    The stock is currently trading below its 200 DMA.

    AstaZenecaDr ReddyGlenmarkLupinNifty Pharma
    Source : Press Release

    Disclaimer: This site is primarily intended for healthcare professionals. Any content/information on this website does not replace the advice of medical and/or health professionals and should not be construed as medical/diagnostic advice/endorsement or prescription. Use of this site is subject to our terms of use, privacy policy, advertisement policy. © 2020 Minerva Medical Treatment Pvt Ltd

    supriya kashyap kashyap
    supriya kashyap kashyap
      Show Full Article
      Next Story
      Similar Posts
      NO DATA FOUND

      Popular Stories

      • Email: info@medicaldialogues.in
      • Phone: 011 - 4372 0751

      Website Last Updated On : 13 Oct 2022 5:14 AM GMT
      Company
      • About Us
      • Contact Us
      • Our Team
      • Reach our Editor
      • Feedback
      • Submit Article
      Ads & Legal
      • Advertise
      • Advertise Policy
      • Terms and Conditions
      • Privacy Policy
      • Editorial Policy
      • Comments Policy
      • Disclamier
      Medical Dialogues is health news portal designed to update medical and healthcare professionals but does not limit/block other interested parties from accessing our general health content. The health content on Medical Dialogues and its subdomains is created and/or edited by our expert team, that includes doctors, healthcare researchers and scientific writers, who review all medical information to keep them in line with the latest evidence-based medical information and accepted health guidelines by established medical organisations of the world.

      Any content/information on this website does not replace the advice of medical and/or health professionals and should not be construed as medical/diagnostic advice/endorsement or prescription.Use of this site is subject to our terms of use, privacy policy, advertisement policy. You can check out disclaimers here. © 2025 Minerva Medical Treatment Pvt Ltd

      © 2025 - Medical Dialogues. All Rights Reserved.
      Powered By: Hocalwire
      X
      We use cookies for analytics, advertising and to improve our site. You agree to our use of cookies by continuing to use our site. To know more, see our Cookie Policy and Cookie Settings.Ok